219 related articles for article (PubMed ID: 2240167)
1. Cyclocreatine inhibits the production of neutrophil chemotactic factors from isolated hearts.
Elgebaly SA; Allam ME; Rossomando EF; Cordis GA; Forouhar F; Farghaly A; Kreutzer DL
Am J Pathol; 1990 Nov; 137(5):1233-41. PubMed ID: 2240167
[TBL] [Abstract][Full Text] [Related]
2. Cyclocreatine inhibits neutrophil accumulation in the myocardium of a canine model of coronary artery occlusion and reperfusion.
Elgebaly SA; Allam ME; Houser S; Hashmi F; Forouhar F; Miano D
J Pharmacol Exp Ther; 1993 Sep; 266(3):1670-7. PubMed ID: 8371165
[TBL] [Abstract][Full Text] [Related]
3. Cardiac derived neutrophil chemotactic factors; preliminary biochemical characterization.
Elgebaly SA; Masetti P; Allam M; Forouhar F
J Mol Cell Cardiol; 1989 Jun; 21(6):585-93. PubMed ID: 2674454
[TBL] [Abstract][Full Text] [Related]
4. Cardiac-derived neutrophil chemotactic factors: detection in coronary sinus effluents of patients undergoing myocardial revascularization.
Elgebaly SA; Hashmi FH; Houser SL; Allam ME; Doyle K
J Thorac Cardiovasc Surg; 1992 May; 103(5):952-9. PubMed ID: 1314922
[TBL] [Abstract][Full Text] [Related]
5. Effect of creatine monohydrate on cardiac function in a rat model of endotoxemia.
Vona-Davis L; Wearden PD; Karne NH; Hill RC
J Surg Res; 2002 Mar; 103(1):1-7. PubMed ID: 11855910
[TBL] [Abstract][Full Text] [Related]
6. The ionic basis of chemotaxis. Separate cation requirements for neutrophil orientation and locomotion in a gradient of chemotactic peptide.
Marasco WA; Becker EL; Oliver JM
Am J Pathol; 1980 Mar; 98(3):749-68. PubMed ID: 6767408
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil chemotactic factors in the tears of giant papillary conjunctivitis patients.
Elgebaly SA; Donshik PC; Rahhal F; Williams W
Invest Ophthalmol Vis Sci; 1991 Jan; 32(1):208-13. PubMed ID: 1846131
[TBL] [Abstract][Full Text] [Related]
8. Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion.
Ferrari R; Raddino R; Di Lisa F; Ceconi C; Curello S; Albertini A; Nayler W
J Thorac Cardiovasc Surg; 1990 May; 99(5):919-28. PubMed ID: 2329831
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones.
Harvath L; Yancey KB; Katz SI
J Immunol; 1986 Aug; 137(4):1305-11. PubMed ID: 3016092
[TBL] [Abstract][Full Text] [Related]
10. Myocardial protection during ischemia by prior feeding with the creatine analog: cyclocreatine.
Jacobstein MD; Gerken TA; Bhat AM; Carlier PG
J Am Coll Cardiol; 1989 Jul; 14(1):246-51. PubMed ID: 2738267
[TBL] [Abstract][Full Text] [Related]
11. The immature and the mature myocardium. Responses to multidose crystalloid cardioplegia.
Magovern JA; Pae WE; Miller CA; Waldhausen JA
J Thorac Cardiovasc Surg; 1988 Apr; 95(4):618-24. PubMed ID: 3352295
[TBL] [Abstract][Full Text] [Related]
12. Age-related changes in the ability of hypothermia and cardioplegia to protect ischemic rabbit myocardium.
Baker JE; Boerboom LE; Olinger GN
J Thorac Cardiovasc Surg; 1988 Nov; 96(5):717-24. PubMed ID: 3184966
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of myocardial protection from ischemic arrest by intracoronary tetrodotoxin administration.
Tyers GF; Todd GJ; Neely JR; Waldhausen JA
J Thorac Cardiovasc Surg; 1975 Feb; 69(2):190-5. PubMed ID: 1113537
[TBL] [Abstract][Full Text] [Related]
14. Is protection of ischemic neonatal myocardium by cardioplegia species dependent?
Baker JE; Boerboom LE; Olinger GN
J Thorac Cardiovasc Surg; 1990 Feb; 99(2):280-7. PubMed ID: 2299865
[TBL] [Abstract][Full Text] [Related]
15. Creatine and cyclocreatine effects on ischemic myocardium: 31P nuclear magnetic resonance evaluation of intact heart.
Osbakken M; Ito K; Zhang D; Ponomarenko I; Ivanics T; Jahngen EG; Cohn M
Cardiology; 1992; 80(3-4):184-95. PubMed ID: 1511465
[TBL] [Abstract][Full Text] [Related]
16. Peroxynitrite, a two-edged sword in post-ischemic myocardial injury-dichotomy of action in crystalloid- versus blood-perfused hearts.
Ma XL; Gao F; Lopez BL; Christopher TA; Vinten-Johansen J
J Pharmacol Exp Ther; 2000 Mar; 292(3):912-20. PubMed ID: 10688604
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C isoform-dependent myocardial protection by ischemic preconditioning and potassium cardioplegia.
Lu K; Otani H; Yamamura T; Nakao Y; Hattori R; Ninomiya H; Osako M; Imamura H
J Thorac Cardiovasc Surg; 2001 Jan; 121(1):137-48. PubMed ID: 11135170
[TBL] [Abstract][Full Text] [Related]
18. [Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: an experiment with isolated rat hearts].
Zhang YJ; Bai XJ; Qi ZM; Wang HX
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3350-3. PubMed ID: 16409843
[TBL] [Abstract][Full Text] [Related]
19. Role of chemotactic factor inactivator in modulating alveolar macrophage-derived neutrophil chemotactic activity.
Robbins RA; Justice JM; Rasmussen JK; Russ WD; Thomas KR; Rennard SI
J Lab Clin Med; 1987 Feb; 109(2):164-70. PubMed ID: 3805869
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotection with pioglitazone is abolished by nitric oxide synthase inhibitor in ischemic rabbit hearts--comparison of the effects of pioglitazone and metformin.
Kawabata H; Ishikawa K
Diabetes Metab Res Rev; 2003; 19(4):299-305. PubMed ID: 12879407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
